BCG Oncology

Phoenix, Arizona 85032-2129

0 studies enrolling now · 14 studies all time

What they study most

Bladder Cancer, Bladder Cancer Recurrence, Bladder Neoplasms, CIS, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors, Carcinoma, Transitional Cell, High Grade, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Non Muscle Invasive, Non Muscle Invasive Bladder Cancer, Non-muscle Invasive Bladder Cancer

Studies at this site

• Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder — Running, not enrolling
• Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin — Running, not enrolling
• Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer — Withdrawn before enrolling
• Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer — Completed
• Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer — Stopped early
• Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure — Completed
• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) — Completed
• Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer — Completed
• Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder — Stopped early
• Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer — Completed
• A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC) — Stopped early
• Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer — Completed
• Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer — Completed
• Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure — Status unconfirmed